Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Surface Oncology Inc (NQ: SURF ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Sep 7, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Surface Oncology Inc Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences August 31, 2023 Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting From Surface Oncology, Inc. Via GlobeNewswire SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF August 07, 2023 From Kahn Swick & Foti, LLC Via Business Wire Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023 August 02, 2023 From Surface Oncology, Inc. Via GlobeNewswire SURFACE ONCOLOGY INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF June 21, 2023 From Kahn Swick & Foti, LLC Via Business Wire SURF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surface Oncology, Inc. Is Fair to Shareholders June 16, 2023 From Halper Sadeh LLC Via Business Wire Coherus to Acquire Surface Oncology June 16, 2023 From Surface Oncology, Inc. Via GlobeNewswire Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023 May 04, 2023 From Surface Oncology, Inc. Via GlobeNewswire Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023 April 18, 2023 – New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models – From Surface Oncology, Inc. Via GlobeNewswire Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 March 16, 2023 From Surface Oncology, Inc. Via GlobeNewswire Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022 March 09, 2023 From Surface Oncology, Inc. Via GlobeNewswire Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference February 28, 2023 From Surface Oncology, Inc. Via GlobeNewswire Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference February 02, 2023 From Surface Oncology, Inc. Via GlobeNewswire Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology January 09, 2023 Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform From Vaccinex, Inc. Via GlobeNewswire Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors January 05, 2023 From Surface Oncology, Inc. Via GlobeNewswire Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting November 07, 2022 Data further support SRF388 and SRF114 clinical development programs From Surface Oncology, Inc. Via GlobeNewswire Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort November 02, 2022 From Surface Oncology, Inc. Via GlobeNewswire VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388 October 19, 2022 From Surface Oncology, Inc. Via GlobeNewswire Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026 September 20, 2021 Via FinancialNewsMedia Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
